Vanguard Group
SLNO

Vanguard Group’s Soleno Therapeutics SLNO Stock Holding History

Vanguard Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$142M Buy
3,060,361
+253,212
+9% +$13.9M ﹤0.01% 1707
2025
Q3 		$190M Buy
2,807,149
+319,317
+13% +$23.7M ﹤0.01% 1562
2025
Q2 		$208M Buy
2,487,832
+621,506
+33% +$46.5M ﹤0.01% 1485
2025
Q1 		$133M Sell
1,866,326
-18,207
-1% -$887K ﹤0.01% 1661
2024
Q4 		$84.7M Buy
1,884,533
+303,806
+19% +$15.7M ﹤0.01% 1938
2024
Q3 		$79.8M Buy
1,580,727
+77,974
+5% +$3.73M ﹤0.01% 1982
2024
Q2 		$61.3M Buy
1,502,753
+533,098
+55% +$22.6M ﹤0.01% 2064
2024
Q1 		$41.5M Buy
969,655
+33
+0% +$1.49K ﹤0.01% 2247
2023
Q4 		$39M Buy
969,622
+914,371
+1,655% +$26M ﹤0.01% 2288
2023
Q3 		$1.63M Buy
55,251
+5,312
+11% +$32.2K ﹤0.01% 3656
2023
Q2 		$214K Hold
49,939
– – ﹤0.01% 4304
2023
Q1 		$107K Hold
49,939
– – ﹤0.01% 4400
2022
Q4 		$98.9K Sell
49,939
-71,147
-59% -$88.5K ﹤0.01% 4395
2022
Q3 		$202K Sell
121,086
-14,634
-11% -$35.6K ﹤0.01% 4414
2022
Q2 		$377K Sell
135,720
-1,070
-0.8% -$2.96K ﹤0.01% 4358
2022
Q1 		$457K Sell
136,790
-836
-0.6% -$4.33K ﹤0.01% 4418
2021
Q4 		$846K Sell
137,626
-275
-0.2% -$2.88K ﹤0.01% 4306
2021
Q3 		$1.91M Hold
137,901
– – ﹤0.01% 4071
2021
Q2 		$2.36M Sell
137,901
-18,194
-12% -$307K ﹤0.01% 3924
2021
Q1 		$2.95M Buy
156,095
+30,873
+25% +$995K ﹤0.01% 3764
2020
Q4 		$3.62M Buy
125,222
+25,063
+25% +$723K ﹤0.01% 3494
2020
Q3 		$3.77M Buy
100,159
+7,870
+9% +$230K ﹤0.01% 3285
2020
Q2 		$3.07M Buy
92,289
+25,541
+38% +$1.11M ﹤0.01% 3305
2020
Q1 		$2.38M Buy
66,748
+28,165
+73% +$1.2M ﹤0.01% 3254
2019
Q4 		$1.7M Buy
38,583
+19,784
+105% +$506K ﹤0.01% 3492
2019
Q3 		$423K Buy
18,799
+2,540
+16% +$81K ﹤0.01% 3850
2019
Q2 		$683K Buy
16,259
+2,007
+14% +$69.4K ﹤0.01% 3770
2019
Q1 		$440K Buy
14,252
+1,786
+14% +$47.5K ﹤0.01% 3794
2018
Q4 		$320K Buy
12,466
+8,061
+183% +$235K ﹤0.01% 3817
2018
Q3 		$143K Buy
4,405
+1,019
+30% +$37K ﹤0.01% 4044
2018
Q2 		$119K Buy
3,386
+60
+2% +$1.76K ﹤0.01% 4036
2018
Q1 		$90K Buy
3,326
+627
+23% +$17.1K ﹤0.01% 4043
2017
Q4 		$73K Hold
2,699
– – ﹤0.01% 4019
2017
Q3 		$105K Buy
2,699
+1,925
+249% +$75.9K ﹤0.01% 3985
2017
Q2 		$30K Sell
774
-130
-14% -$6.03K ﹤0.01% 4051
2017
Q1 		$46K Buy
904
+76
+9% +$4.48K ﹤0.01% 4032
2016
Q4 		$50K Buy
828
+15
+2% +$1.04K ﹤0.01% 4033
2016
Q3 		$59K Hold
813
– – ﹤0.01% 4022
2016
Q2 		$71K Buy
813
+109
+15% +$9.94K ﹤0.01% 4053
2016
Q1 		$63K Buy
704
+356
+102% +$34.9K ﹤0.01% 4063
2015
Q4 		$48K Buy
348
+99
+40% +$14.5K ﹤0.01% 4138
2015
Q3 		$40K Sell
249
-495
-67% -$89.6K ﹤0.01% 4151
2015
Q2 		$157K Buy
744
+289
+64% +$111K ﹤0.01% 4076
2015
Q1 		$218K Buy
+455
New +$135K ﹤0.01% 3987

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Group's SLNO Position: Q4 2025 in Review

Vanguard Group increased its Soleno Therapeutics (SLNO) stake by 9% in Q4 2025, buying an estimated $13.9M and bringing the position to 3,060,361 shares worth $142M. The position accounts for ﹤0.01% of the portfolio, ranked #1707.

Vanguard Group first reported a position in SLNO in Q1 2015 and has held it in 44 quarters since. The position peaked at $208M in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Vanguard Group held 3,060,361 shares of Soleno Therapeutics worth $142M as of Q4 2025.
  • Vanguard Group bought 253,212 Soleno Therapeutics shares in Q4 2025, an estimated $13.9M.
  • Soleno Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1707 holding.
  • Vanguard Group first reported a position in Soleno Therapeutics in Q1 2015 and has held it in 44 quarters since.
  • Vanguard Group's Soleno Therapeutics position peaked at $208M in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.